Gerardo Abel Fernández 🇦🇷, born on October 29, 1976, in Bahía Blanca, Argentina, is a researcher specializing in neuroscience and cognitive science 🧠. He is a professor and adjunct researcher at CONICET, focusing on eye movement-based biomarkers for neurodegenerative diseases 👀. His work integrates philosophy, cognitive psychology, and technology to advance Alzheimer’s diagnosis 🏥.
Profile
Education 🎓
🎓 Gerardo Abel Fernández obtained a degree in Philosophy (2003) from Universidad Nacional del Sur (UNS), Argentina, with a specialization in Logic and Epistemology. He later pursued a PhD in Philosophy (2011) at UNS, with his thesis titled “Dynamic word processing during reading: Mental strategies driving visual exploration”, earning a perfect 10/10 with special mention. His academic journey includes postdoctoral research as a fellow at AGENCIA (ANPCYT) and the DAAD Max Planck Institute in Berlin. His educational background bridges philosophy, neuroscience, and cognitive psychology, forming a solid foundation for his pioneering research in eye movement analysis and Alzheimer’s biomarkers. His expertise in cognitive science and technological innovation has led to the development of diagnostic tools for early neurodegenerative disease detection. 📚🔍🧠
Experience 👨🏫
💼 Dr. Gerardo Abel Fernández has extensive experience in neuroscience research and technological innovation. He served as a Professor of Audiovisual Language at UNS (2011–2013) and is currently an Adjunct Researcher at CONICET, focusing on non-endemic degenerative pathologies. He has worked as a Visiting Scholar at Heriot-Watt University and Strathclyde University (UK), contributing to the development of eye-tracking biomarkers for Alzheimer’s disease. Dr. Fernández is also a scientific reviewer for prestigious journals like PlosOne, Journal of Alzheimer’s Disease, and Neuropsychologia. As CTO of Viewmind, he leads biocognitive and functional performance measurement innovations. He has patented cognitive evaluation methods and received grants from institutions like ANPCYT and DAAD. His interdisciplinary expertise spans cognitive neuroscience, machine learning applications in diagnostics, and technological development for neurodegenerative disease assessment. 🏅🔬👁️
Research Interests 🔬
🔬 Dr. Gerardo Abel Fernández specializes in cognitive neuroscience, neurodegenerative disease biomarkers, and eye-tracking technology. His research focuses on early Alzheimer’s detection through oculomotor behavior analysis. He has developed innovative methods to study visual exploration, reading difficulties, and memory impairments in neurodegenerative conditions. His work integrates machine learning and artificial intelligence for cognitive assessment tools. As a Visiting Scholar in the UK, he contributed to developing biomarkers for Alzheimer’s disease. His patented eye-tracking system has clinical applications in detecting mild cognitive impairment and Alzheimer’s disease. He has published extensively in peer-reviewed journals, exploring predictive eye movement models and their correlation with cognitive decline. His cutting-edge research bridges philosophy, neuroscience, and technology, offering non-invasive diagnostic solutions for early-stage neurodegeneration. His ultimate goal is to revolutionize cognitive healthcare through technological innovation. 🧠👁️📊
Awards & Recognitions 🏅
🏆 Dr. Gerardo Abel Fernández has received numerous awards for his contributions to neuroscience, cognitive evaluation, and Alzheimer’s diagnostics. His eye-tracking research for Alzheimer’s detection earned the Dr. José Borda Clinical Psychiatry Prize at the 22nd International Congress of Psychiatry. He won the Novartis Innovation Award for his work on measuring cognitive performance in health and disease. As CTO of Viewmind, his team received international recognition, including the Fit4Start Luxembourg Award for health applications and the Medica Innovation Prize in Düsseldorf. His research and patented cognitive evaluation equipment have been acknowledged by ANMAT (Argentina’s National Administration of Drugs, Foods, and Medical Technology) and INPI (Argentina’s National Patent Office). Dr. Fernández’s groundbreaking innovations in neurocognitive assessments have positioned him as a leading figure in technological advancements for early Alzheimer’s detection. 🏅🧠🔬
Publications 📚
-
Oculomotor behaviors and integrative memory functions in the alzheimer’s clinical syndrome
Journal of Alzheimer’s Disease
2021 | Journal article
-
A non-invasive tool for attention-deficit disorder analysis based on gaze tracks.
ACM International Conference Proceeding Series
2019 | Conference paper
-
Microsaccadic behavior when developing a complex dynamical activity
Journal of Integrative Neuroscience
2018 | Journal article